GSK Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 21.61% compared to GSK PLC's net margin of -227.46%. GSK PLC's return on equity of 23.08% beat BioNTech SE's return on equity of -3.91%.

GSK PLC has a consensus price target of $41.59, signalling upside risk potential of 14.84%. On the other hand BioNTech SE has an analysts' consensus of $132.57 which suggests that it could grow by 43.97%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

GSK PLC has a beta of 0.539, which suggesting that the stock is 46.147% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.29%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than BioNTech SE quarterly revenues of $192.3M. GSK PLC's net income of $2B is higher than BioNTech SE's net income of -$437.5M. Notably, GSK PLC's price-to-earnings ratio is 18.78x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.86x versus 7.46x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Haleon PLC has a net margin of 21.61% compared to GSK PLC's net margin of 8.37%. GSK PLC's return on equity of 23.08% beat Haleon PLC's return on equity of 8.91%.

GSK PLC has a consensus price target of $41.59, signalling upside risk potential of 14.84%. On the other hand Haleon PLC has an analysts' consensus of $11.13 which suggests that it could grow by 7.04%. Given that GSK PLC has higher upside potential than Haleon PLC, analysts believe GSK PLC is more attractive than Haleon PLC.

GSK PLC has a beta of 0.539, which suggesting that the stock is 46.147% less volatile than S&P 500. In comparison Haleon PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.29%. Haleon PLC offers a yield of 1.63% to investors and pays a quarterly dividend of $0.12 per share. GSK PLC pays 94.91% of its earnings as a dividend. Haleon PLC pays out 39.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than Haleon PLC quarterly revenues of $3.5B. GSK PLC's net income of $2B is higher than Haleon PLC's net income of $295.8M. Notably, GSK PLC's price-to-earnings ratio is 18.78x while Haleon PLC's PE ratio is 25.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.86x versus 3.32x for Haleon PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.61% compared to GSK PLC's net margin of -907.48%. GSK PLC's return on equity of 23.08% beat Moderna's return on equity of -29.23%.

GSK PLC has a consensus price target of $41.59, signalling upside risk potential of 14.84%. On the other hand Moderna has an analysts' consensus of $46.66 which suggests that it could grow by 94.24%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.539, which suggesting that the stock is 46.147% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.29%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than Moderna quarterly revenues of $107M. GSK PLC's net income of $2B is higher than Moderna's net income of -$971M. Notably, GSK PLC's price-to-earnings ratio is 18.78x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.86x versus 2.98x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 21.61% compared to GSK PLC's net margin of 82.81%. GSK PLC's return on equity of 23.08% beat Novavax's return on equity of --.

GSK PLC has a consensus price target of $41.59, signalling upside risk potential of 14.84%. On the other hand Novavax has an analysts' consensus of $15.29 which suggests that it could grow by 156.47%. Given that Novavax has higher upside potential than GSK PLC, analysts believe Novavax is more attractive than GSK PLC.

GSK PLC has a beta of 0.539, which suggesting that the stock is 46.147% less volatile than S&P 500. In comparison Novavax has a beta of 3.210, suggesting its more volatile than the S&P 500 by 220.956%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.29%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $9.5B, which are larger than Novavax quarterly revenues of $626.3M. GSK PLC's net income of $2B is higher than Novavax's net income of $518.6M. Notably, GSK PLC's price-to-earnings ratio is 18.78x while Novavax's PE ratio is 2.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.86x versus 0.81x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.